Single-dose intravenous sodium valproate (Depakine) versus dexamethasone for the treatment of acute migraine headache: a double-blind randomized clinical trial.
- Author:
Narges KARIMI
1
;
Mahdiye TAVAKOLI
;
Jamshid Yazdani CHARATI
;
Mastoureh SHAMSIZADE
Author Information
- Publication Type:Clinical Trial ; Randomized Controlled Trial ; Original Article
- Keywords: Migraine disorders; Dexamethasone; Valproic acid; Acute; Therapeutics
- MeSH: Adult; Dexamethasone*; Epilepsy; Headache; Humans; Injections, Intravenous; Migraine Disorders*; Outcome Assessment (Health Care); Recurrence; Sodium*; Statistics as Topic; Valproic Acid*; Visual Analog Scale
- From: Clinical and Experimental Emergency Medicine 2017;4(3):138-145
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: Migraine headache is a chronic and disabling condition in adults. Some studies have investigated the efficacy of sodium valproate in the treatment of acute migraine, but the effectiveness and tolerability of intravenous valproate as abortive therapy remains unclear. This study aimed to evaluate the effects of sodium valproate and dexamethasone in the treatment of acute migraine. METHODS: We conducted a double-blind randomized clinical trial including 90 patients aged 18 to 65 years with acute migraine headache but no aura. Patients were randomized to receive intravenous dexamethasone (8 mg) or sodium valproate (400 mg) diluted into 4 mL of normal saline. The primary outcome measure was pain relief after 0.5, 1, 3, or 6 hours after administration. The secondary outcome criteria were the associated symptom recovery, rate of headache recurrence after 24 hours, and medication side effects. Pearson’s chi square and the t-test were employed in the data analysis. RESULTS: Of the 90 patients, 80 were investigated. The percentage of headache improvement at 0.5 hours after treatment was 55% and 67.5% in the sodium valproate and dexamethasone groups, respectively. Before-treatment and 0.5 hour after treatment pain severity visual analog scale scores were 9.05±0.90 and 3.8±3.09 in the sodium valproate group and 8.92±0.79 and 3.10±2.73 in the dexamethasone group, respectively. There were no significant intergroup differences. CONCLUSION: This randomized clinical trial showed that the intravenous injection of sodium valproate 400 mg has similar effects to those of dexamethasone for improving acute migraine headache.
